MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Exclusion Criteria

• •Participant has abnormal liver function or history of liver disease.
• •Participant has lymphoma, leukemia or any malignancy within the past 5 years (except for resected basal/squamous skin carcinomas without metastases within 3 years).
• •Participant has breast cancer within 10 years.
• •Participant has active optic glioma or other low-grade glioma requiring treatment.
• •Participant has abnormal QT interval corrected or other heart disease within 6 months.
• •Participant has a history of retinal pathology, risk factors for retinal vein occlusion or has a history of glaucoma.
• •Participant has known malabsorption syndrome or gastrointestinal conditions that would impair absorption of mirdametinib (PD-0325901).
• •Participant has received NF1 PN-targeted therapy within 45 days.
• •Participant previously received or is currently receiving therapy with mirdametinib (PD-0325901) or any other MEK1/2 inhibitor.
• •Participant has received radiation therapy within 6 months or has received radiation to the orbit at any time.
• •Participant is unable to undergo or tolerate MRI.
• •Participant has active bacterial, fungal or viral infection.
• •Participant has experienced other severe acute or chronic medical or psychiatric conditions within 1 year.